تحسين النتائح
ترتيب حسب
من
الى
الصفحة 1
الصفحة 1
Manifestations dermatologiques des maladies du système hématopoïétique et oncologie dermatologique : Dermatologie et médecine ; Vol.3 = Dermatological manifestations of diseases of the hematopoietic system anddermatological oncology : Dermatology and medicine ; Vol.3
Provides an update on all the disorders of the hematopoietic system with dermatological expression or with a cutaneous origin. Myeloproliferative and myelodysplastic syndromes, leukemias, lymphomas and cutaneous histiocytoses are thus widely described in the light of the latest clinical (classification, new entities) and therapeutic advances.
Leptomeningeal Metastases
Leptomeningeal Metastases provides the reader with an overview of the state-of-the-art therapy for the leptomeningeal patient with additional information on epidemiology, symptom management, new clinical trials, and current basic research in animal models for experimental therapies. "Leptomeningeal metastases remains a devastating manifestation of hematologic malignancies and solid tumors. Leading figures in the field review the pathophysiology and clinical consequences of this process. State-of-the-art treatment strategies are presented highlighting advances in current management."
Chronic Lymphocytic Leukemia
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the Western world. It is also the prototype of B-cell chronic lymphoid malignancies and of their ramifications within the fields of hematology, immunology and oncology. developments of basic science into effective new approaches to the patient.
Cancerimmunotherapies : Solid tumors and hematologic malignancies
Presents the clinical scope of cancer immunotherapeutic agents for solid tumors and Hematologic malignancies, elaborates on the scientific details of their modes of action, and presents the impact of these agents on oncology, patients and the broader healthcare system. At present, cancer immunotherapies fall broadly into three categories: immune checkpoint inhibitors (ICIs), adoptive T cell therapies, and cancer vaccines which have distinct mechanisms of action. Immune checkpoint inhibitors rely upon disrupting tumor antigen recognition as self by the immune system through inhibition of checkpoint molecules. Adoptive T cell therapies involve the engineering of T cells ex vivo to target and destroy tumor cells. The first part of this book will provide an overview of the discovery and mechanistic details of the technology. The second part will be devoted to elaborating on the clinical outcomes, successes and limitations for specific tumor subtypes, which includes both solid tumors and hematologic malignances for both pediatric and adult populations.
Cancer in adolescents and young adults
The chapters highlight the initial efforts of this Committee in addressing the scope of the problem of adolescent and young adult underrepresentation in clinical trials and offer evidence that such adiscrepancy may partially explain outcome differences.In addition, these chapters present information about biologic differences between specific cancer subtypes most common in younger children and those exhibited by the same cancers in adolescents and young adults, and offer plausible explanations for outcome differences as well as potential treatment strategies.
Cancer immunotherapy : Methods and protocols
Details multiple areas of new and emerging methods to develop the next generation of immunotherapy treatments. Chapters guide readers through analysis and characterisation of the interactions between tumour and immune cells, and cell engineering tools for cancer treatment, to provide a unique and compelling set of techniques instrumental to work with, and engineer, immune cells. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls.
Cancer drug resistance
In Cancer Drug Resistance, leading scientists from the best academic institutions and industrial laboratories summarize and synthesize the latest discoveries concerning the changes that occur in tumor cells as they develop resistance to a wide variety of anticancer therapeutics, as well as suggest new approaches to the biology of drug resistance that may afford new therapeutic opportunities.
Acute Promyelocytic Leukemia : Molecular Genetics, Mouse Models and Targeted Therapy
Over the past 10 years, work on acute promyelocytic leukemia (APL) has become the paradigm of translational research that began with the discovery of a recurrent chromosomal translocation, followed by the identification of the genes and proteins involved, finding their molecular functions in transcriptional control, establishing mouse models and culminating in the development of targeted therapy.
Acute Myelogenous Leukemia
The focus is on selected critical molecular determinants of AML pathogenesis and pathophysiology and the exploitation of these factors by diverse therapeutic agents and modalities. Bringing together new concepts and findings in the basic and clinical science of AML, the book emphasizes the molecular basis for new therapies that stand to have the greatest potential impact on the clinical face of these diseases. The text provides insights into selected novel strategies currently and prospectively being developed, including interruption of specific signal transduction pathways, modulation of gene expression, attempts to reinstate differentiation, and immunomodulation.
